Genelux develops cancer immunotherapies based on a modified vaccinia virus that infects and destroys tumor cells. GNLX reports earnings on Wed, Nov 4, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 25 | Roth MKM | Initiated | Buy |
Seasonality
How GNLX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2023.
Whale Options Flow
90DNo whale options trades in GNLX in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether GNLX is in one of them and how their past GNLX trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered GNLX in an article yet. Here's the latest on the wider market.
About GENELUX
Genelux is a biopharmaceutical company based in Westlake Village, California, that develops cancer treatments built on a modified vaccinia virus. Its lead candidate, Olvi-Vec, is designed to infect and destroy tumor cells while prompting the immune system to attack cancer throughout the body. The company is testing it in ovarian cancer, lung cancer and small cell lung cancer, aiming at patients whose tumors have responded poorly to standard treatments such as chemotherapy. It also operates a manufacturing facility in San Diego and has licensed rights to Olvi-Vec in China to a partner.
- Headquarters
- Westlake Village, CA